Seeking Alpha

Peregrine Pharmaceuticals (PPHM +9.1%) moves up after its FQ1 beat estimates across the board on...

Peregrine Pharmaceuticals (PPHM +9.1%) moves up after its FQ1 beat estimates across the board on fewer than anticipated losses, despite a double digit Y/Y decline in total revenue. The stock soared on Friday, after the company said a recent Phase IIb trial of its lung cancer treatment bavituximab produced interim data showing statistically significant improvement in overall survival.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs